Compare Medpace Holdings Inc (MEDP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Medpace Holdings Inc trades at $609.54 (market cap $16.90B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.9× Medpace Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | REGN | |
|---|---|---|
Market Cap | $16.90B | $82.06B |
Sector | Technology | Health |
52-Week High | $620.59 | $812.27 |
52-Week Low | $393.42 | $555.51 |
Enterprise Value | $16.52B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
